Pressure overload induced cardiac hypertrophy, such as that caused by chronic hypertension, is a key risk factor for heart failure. Accumulating evidence from studies in patients and animal models suggests that cardiac hypertrophy induced by the chronic pressure overload is not a compensatory but rather is a maladaptive process. Thus, modulation of pathological myocardial hypertrophy is increasingly recognized as a potentially promising approach in the prevention of development of heart failure. Despite intensive research efforts over several decades, the molecular mechanisms of hypertrophic heart failure are not fully understood. Our recent study found that the valosin-containing protein (VCP), a protein which is previously uncharacterized in the heart, represents a mediator of cardioprotection that is directly relevant to the condition of cardiac hypertrophy and dysfunction induced by hypertension in patients. The originality of this proposal is based on our preliminary findings that VCP expression is significantly down-regulated in the pressure overloaded hearts in variant animal models. We also found that cardiac specific overexpression of VCP in a transgenic mouse significantly attenuates the pressure overload induced cardiac hypertrophy and dysfunction, while impaired VCP accelerates cardiac dysfunction under pressure overload and also hastens age related cardiomyopathy. We also found that VCP presents a dual regulatory effect on the signaling of mechanistic target of rapamycin (mTOR) in the heart. As supported by the Preliminary Data, our overall hypothesis is that VCP is an essential mediator of cardioprotection against pressure-overload induced cardiac hypertrophy and dysfunction which is mediated by a mechanism of regulating growth and survival of cardiomyocytes via modulating mTOR signaling. Thus, in this proposal, we will elucidate further the physiological relevance and the underlying mechanisms of VCP in the heart at baseline and under pressure overload through two Specific Aims.
Our first Aim i s to determine the physiological relevance of VCP on the cardiac growth and function during aging and under pressure overload. We will test our hypothesis that an insufficiency of VCP is responsible for the pathogenesis of cardiac hypertrophy and dysfunction during aging and under pressure overload of heart, and an overexpression VCP will provide protection against the cardiac deterioration under these conditions.
Our second Aim i s to elucidate the molecular mechanisms of cardiac protection conferred by VCP. We will test our hypothesis that VCP acts as a unique dual regulator for mTOR complexes by selectively activating the survival complex mTORC2 but inhibiting the growth-promoting complex mTORC1 under the pathological stress. We also hypothesize that this selective effect of VCP depends on its N-terminal regulatory domain. Based on our extensive preliminary data and previous publications, we strongly believe that our proposed studies using the comprehensive in vivo, ex vivo and in vitro approaches will elucidate the specific mechanisms involved in the cardiac protection by VCP under pressure overload which will provide a new strategy for preventing and treating the heart failure. .

Public Health Relevance

Heart failure is a leading cause of hospitalization and mortality despite the availability of significant therapeutic options. Cardiac hypertrophy in response to pressure overload, such as chronic hypertension, is a major predictor for the development of heart failure, and is also an independent risk factor for myocardial infarction, arrhythmia and sudden death. Modulation of pathological myocardial hypertrophy is increasingly recognized as a potentially promising approach in the prevention of development of heart failure. Our recent study found that the valosin-containing protein (VCP), a protein which is previously uncharacterized in the heart, represents a mediator of cardioprotection that is directly relevant to the condition of cardiac hypertrophy and dysfunction induced by hypertension in patients. In this proposal, we will elucidate further the physiological relevance and the underlying mechanisms of VCP in the heart at baseline and under pressure overload. This study will prove critical to develop novel therapeutic avenues for preventing hypertensive heart failure by the manipulation of VCP expression.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56HL137962-01
Application #
9565795
Study Section
Hypertension and Microcirculation Study Section (HM)
Program Officer
Wong, Renee P
Project Start
2017-09-22
Project End
2018-08-31
Budget Start
2017-09-22
Budget End
2018-08-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Loma Linda University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
009656273
City
Loma Linda
State
CA
Country
United States
Zip Code
92350
Stoll, Shaunrick; Wang, Charles; Qiu, Hongyu (2018) DNA Methylation and Histone Modification in Hypertension. Int J Mol Sci 19:
Xu, Shiyue; Tao, Jun; Yang, Liu et al. (2018) E2F1 Suppresses Oxidative Metabolism and Endothelial Differentiation of Bone Marrow Progenitor Cells. Circ Res 122:701-711
Fan, Jingjing; Qiu, Lin; Shu, Hongyang et al. (2018) Recombinant frizzled1 protein attenuated cardiac hypertrophy after myocardial infarction via the canonical Wnt signaling pathway. Oncotarget 9:3069-3080
Hays, Tristan T; Ma, Ben; Zhou, Ning et al. (2018) Vascular smooth muscle cells direct extracellular dysregulation in aortic stiffening of hypertensive rats. Aging Cell 17:e12748
Leimena, Christiana; Qiu, Hongyu (2018) Non-Coding RNA in the Pathogenesis, Progression and Treatment of Hypertension. Int J Mol Sci 19:
Zhou, Ning; Lee, Jia-Jye; Stoll, Shaunrick et al. (2017) Rho Kinase Regulates Aortic Vascular Smooth Muscle Cell Stiffness Via Actin/SRF/Myocardin in Hypertension. Cell Physiol Biochem 44:701-715
Zhou, Ning; Ma, Ben; Stoll, Shaunrick et al. (2017) The valosin-containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload. Aging Cell 16:1168-1179
Zhou, Ning; Stoll, Shaunrick; Qiu, Hongyu (2017) VCP represses pathological cardiac hypertrophy. Aging (Albany NY) 9:2469-2470